Dean Rosales's questions to DaVita Inc (DVA) leadership • Q1 2025
Question
Dean Rosales from Wolfe Research questioned if the full-year guidance for revenue per treatment (RPT) growth of 4.5% to 5.5% remains intact.
Answer
CFO Joel Ackerman confirmed there is no change to the full-year RPT guidance. He noted that while they expect slightly more contribution from oral phosphate binders, the overall forecast remains within the previously stated range.